Kyverna Therapeutics, Inc. KYTX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s accounts payable?
- Kyverna Therapeutics, Inc. (KYTX) reported accounts payable of $11.6M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s accounts payable changed year-over-year?
- Kyverna Therapeutics, Inc.'s accounts payable increased by 37.0% year-over-year, from $8.47M to $11.6M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s accounts payable?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s accounts payable has grown at a 121.1% compound annual growth rate (CAGR), from $5.46M to $26.71M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.